IP Library Granted Patent US 10,179,918
Granted Patent B2
US 10,179,918 · App. 15/141,333 · Granted Jan 15, 2019

Methods and compositions for increasing transgene activity

Inventor: Gregory J. Cost (Richmond, CA)
Assignee: Sangamo Therapeutics, Inc.
C12N15/86C12N15/85C12N2730/10143C12N2740/16043C12N2740/16045C12N2830/48C12N2840/105C12N2840/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,179,918
App. No.
15/141,333
Granted
Jan 15, 2019
Kind
B2
Abstract

Methods and compositions for increasing transgene expression and/or activity, including for increasing nuclease-mediated genomic modifications.

Claims (11)

1. A method of increasing nuclease activity in a cell, the method comprising: introducing an mRNA comprising a 3′ untranslated region (3′ UTR) and encoding at least one component of one or more nucleases into the cell, wherein the mRNA comprises a woodchuck hepatitis virus posttranslational regulatory element (WPRE) as shown in any of SEQ ID NOs:1-3 in the 3′ UTR.

2. The method of claim 1 , wherein the WPRE is a wild-type WPRE.

3. The method of claim 1 , wherein the nuclease is a zinc finger nuclease, a TALEN and/or a CRISPR/Cas and/or a Cfp1 CRISPR/Cas nuclease system.

4. The method of claim 1 , further comprising subject the cells to cold-shock conditions.

5. An isolated mRNA comprising a WPRE sequence as shown in any of SEQ ID NO:1-3 in the 3′ UTR and a sequence encoding at least one component of a nuclease or a transcription factor (TF).

6. The mRNA of claim 5 , wherein the sequence encodes a nuclease.

7. The mRNA of claim 5 , wherein the nuclease is a zinc finger nuclease, a TALEN and/or at least one component of a CRISPR/Cas nuclease system.

8. The mRNA of claim 5 , wherein the Cas protein is a Cas and/or Cfp1 protein.

9. The mRNA of claim 5 , wherein the sequence encodes a transcription factor.

10. The mRNA of claim 9 , wherein the transcription factor is a ZF-TF, a TALE-TF or a CRISPR/Cas TF.

11. The mRNA of claim 5 , further comprising a polyA sequence.

Assignments (2)
CHANGE OF NAME Recorded Oct 22, 2018
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 047287/0688 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2016
From: COST, GREGORY J
To: SANGAMO BIOSCIENCES, INC.
Reel/Frame 040103/0417 →
Continuity (2)
Provisional Application 62158277 · May 7, 2015
Related Publication 20160326548A1 · Nov 10, 2016
Cited By (1)
US 12,630,839